From Yahoo Finance: 2025-05-13 08:54:00

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is among the best low-priced biotech stocks to buy now. Analysts discuss how tariffs and policy risks are impacting the sector, estimating a 50% tariff rate and -4-5% EPS impact. Despite challenges, many biotech stocks are trading at a decade-low P/E multiple, offering potential buying opportunities.

Hedge funds are interested in low-priced biotech stocks, with Rocket Pharmaceuticals, Inc. (RCKT) standing out. The company focuses on gene therapy for rare pediatric diseases like Fanconi Anemia. Analysts maintain a bullish stance on RCKT, citing promising developments and a strategic market position. Rocket ranks 2nd on the list of best low priced biotech stocks.

Rocket Pharmaceuticals, Inc. (RCKT) is actively advancing a gene therapy program for a genetic disease. Analysts believe the company’s approach could lead to positive outcomes and robust protein expression. J.P. Morgan also maintains a Buy rating on the stock with a $44.00 price target. While RCKT shows promise, some AI stocks may offer higher returns in a shorter timeframe.

The most favored nation policy in drug pricing is causing uncertainty in the biotech sector. The US pays 40-50% more for drugs compared to other developed nations, leading to potential price drops. Despite challenges, biotech stocks are trading at attractive valuations and may see an increase in value in the future.



Read more at Yahoo Finance: Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now?